Literature DB >> 17442473

Buprenorphine substitution treatment in France: drug users' views of the doctor-user relationship.

Anne Guichard1, France Lert, Jean-Marc Brodeur, Lucie Richard.   

Abstract

The French system for drug substitution, or maintenance treatment, established in 1996, differs from the often strict conditions attached to methadone clinics in other countries. Because of the predominant role of general practitioners and the flexible prescription rules for Subutex in France, the relationship between the physician and the drug user becomes a central element in the treatment. This article deals with the expectations that these users have of the physician, and their perception of his or her attitude towards them. In order to identify possible reasons for the absence of treatment compliance and of Subutex misuse, it focuses on the users' assessment of the physician's response to the problems they report. This study, based on a diversified convenience sample of 28 persons (19 men, 9 women) in treatment, showed 4 patterns of relationships between physicians and users, which differed in their focus: (1) closely focused on the posology of the prescription; (2) compliance with the prescribed regimen is the main issue in a relationship dominated by the physician; (3) an alliance between the physician and the user who is acknowledged as a person, and (4) a instrumental solely on the part of the user, who comes to procure a free, legal drug from a doctor's office. In all four case types, users had difficulty reporting other drug use or intravenous Subutex injection within this relationship, in which the stigma attached to drug dependence seems to reappear. Moreover, the lack of clarity about the treatment objectives and the time frame of the consultation limits the users' ability to integrate the treatment into their lives and to commit themselves to it. The heterogeneity and fragility of the users' situations, and the treatment objectives require regular assessment during contact with the physician. This constant reappraisal of the situation with the physician should help to optimize the treatment and avoid the hiatus that can generate or continue "misuse."

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442473      PMCID: PMC1950347          DOI: 10.1016/j.socscimed.2007.02.049

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  29 in total

1.  Active heroin injectors' perceptions and use of methadone maintenance treatment: cynical performance or self-prescribed risk reduction?

Authors:  S Koester; K Anderson; L Hoffer
Journal:  Subst Use Misuse       Date:  1999-12       Impact factor: 2.164

2.  Appreciating the user's perspective: listening to the "methadonians".

Authors:  Michael Montagne
Journal:  Subst Use Misuse       Date:  2002-03       Impact factor: 2.164

3.  The methadone street scene: the addict's view.

Authors:  M H Agar; R C Stephens
Journal:  Psychiatry       Date:  1975-11       Impact factor: 2.458

4.  Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.

Authors:  J P Moatti; M P Carrieri; B Spire; J A Gastaut; J P Cassuto; J Moreau
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

5.  Ambivalence toward methadone treatment among intravenous drug users.

Authors:  A Rosenblum; S Magura; H Joseph
Journal:  J Psychoactive Drugs       Date:  1991 Jan-Mar

6.  Folks and professionals: different models for the interpretation of drug use.

Authors:  M H Agar
Journal:  Int J Addict       Date:  1985-01

7.  "It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment.

Authors:  D E Hunt; D S Lipton; D S Goldsmith; D L Strug; B Spunt
Journal:  Int J Addict       Date:  1985 Nov-Dec

8.  Getting the treatment: recycling women addicts.

Authors:  M Rosenbaum; S Murphy
Journal:  J Psychoactive Drugs       Date:  1981 Jan-Mar

9.  Do patients' perceptions of their counselors influence outcomes of drug treatment?

Authors:  Nagalakshmi D Kasarabada; Yih-Ing Hser; Sharon M Boles; Yu Chuang Huang
Journal:  J Subst Abuse Treat       Date:  2002-12

10.  Methadone dosage and retention of patients in maintenance treatment.

Authors:  J R Caplehorn; J Bell
Journal:  Med J Aust       Date:  1991-02-04       Impact factor: 7.738

View more
  6 in total

1.  Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch
Journal:  J Subst Abuse Treat       Date:  2020-01-21

2.  Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach.

Authors:  Perrine Roux; Patrizia M Carrieri; Julien Cohen; Isabelle Ravaux; Bruno Spire; Michael Gossop; Sandra D Comer
Journal:  Harm Reduct J       Date:  2011-11-28

Review 3.  Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2014-12-30

4.  A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study.

Authors:  Joan Trujols; Ioseba Iraurgi; Eugenia Oviedo-Joekes; Joan Guàrdia-Olmos
Journal:  Patient Prefer Adherence       Date:  2014-01-21       Impact factor: 2.711

5.  The management of opiate use disorders in France: results of an observational survey of general practitioners.

Authors:  Pierre Poloméni; Claude Bronner; Fréderic Fry; Bruno Ravoninjatovo; Mélina Fatseas
Journal:  Addict Sci Clin Pract       Date:  2015-06-28

6.  Opiate dependents' experiences of the therapeutic relationship in methadone centers; a qualitative study.

Authors:  Nabi Banazadeh; Ali Kheradmand; Heidarali Abedi
Journal:  Addict Health       Date:  2009
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.